Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical companies, such as the makers of Xarelto, possess a duty to ensure that their drugs are reasonably protected for use – and failure to do so might be grounds for compensation. Our lawyers are operating tough to obtain those hurt by the drug the compensation they’re entitled to.
Although bleeding can be a typical complication linked with anticoagulants, it has been alleged that Xarelto is much more hazardous than conventional blood thinners because no antidote exists to reverse its blood-thinning effects. This implies that, inside the occasion of an emergency, sufferers might be at threat for irreversible bleeding troubles, including life-threatening internal and gastrointestinal hemorrhaging.
In the event you or possibly a loved one suffered a critical bleeding occasion soon after taking Xarelto, you might have legal recourse. For much more info, get in touch with us nowadays to have your case reviewed, free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for previous and future medical bills, lost wages, discomfort and suffering and, in circumstances of death, funeral expenses. In addition, they may be searching for punitive damages, which are generally awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective implies of stopping Xarelto users from bleeding in the event of an emergency. Plaintiffs within the lawsuits allege significant and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug wa.l.r.u.scv.kd as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing unsafe clotting.
Visit this page for far more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.